Login to Your Account

Insmed makes ‘Arikayce’ that culture conversion trumps phase II primary endpoint miss

By Marie Powers
Staff Writer

Wednesday, March 26, 2014
Early Wednesday, Insmed Corp. provided a detailed debriefing of data from the phase II trial of Arikayce (previously Arikace), its inhaled liposomal amikacin, to treat patients with resistant nontuberculous mycobacterial (NTM) lung infections.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription